FDA Proposes Permanent Ban on Compounded Semaglutide and Tirzepatide

On April 30, 2026, the FDA announced it is proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The Federal Register notice states that the agency found "no clinical need for outsourcing facilities to compound these drugs from bulk substances."

This proposal specifically targets Section 503B outsourcing facilities — FDA-registered compounding operations that can produce and distribute drugs at scale without individual patient prescriptions. These are distinct from 503A compounding pharmacies, which fill individual prescriptions based on a prescriber-patient relationship.

If finalized, the rule would eliminate the legal pathway for large-scale production of compounded semaglutide, tirzepatide, and liraglutide. Public comments are being accepted through June 29, 2026 via the Federal Register docket.

The FDA’s proposal cites significant safety concerns with compounded GLP-1 products. As of early 2025, the agency had received:

455+ adverse event reports linked to compounded semaglutide 320+ adverse event reports linked to compounded tirzepatide

Many of these reports involved dosing errors from patients self-administering incorrect doses from multi-dose vials — a format common in compounding but not used by brand-name products (which use pre-filled, single-dose pens with built-in dose controls).

Additional concerns include sterility issues with compounded injectables, inconsistent potency between batches, and the use of salt forms (such as semaglutide sodium) that differ from the FDA-approved formulations and lack independent safety and efficacy data.

The compounded GLP-1 market emerged during drug shortages that allowed compounding pharmacies to legally produce copies of shortage drugs:

2022–2024: Explosive demand for semaglutide and tirzepatide created sustained drug shortages. During shortages, both 503A and 503B compounders could legally produce these drugs.

October 2024: FDA declared the tirzepatide shortage resolved. Compounding of tirzepatide was no longer protected by shortage status.

February 2025: FDA declared the semaglutide shortage resolved. Same implications for semaglutide compounding.

April 30, 2026: FDA proposes permanent exclusion from the 503B bulks list, finding no clinical need for continued compounding.

The trajectory is clear: the FDA is systematically closing every legal pathway for compounded GLP-1 production. The compounded GLP-1 market, estimated at $1–2 billion annually, faces regulatory extinction.

The 503B ban arrives alongside several developments that collectively reshape GLP-1 access:

Medicare GLP-1 Bridge ($50/month starting July 2026) makes brand-name products affordable for Medicare beneficiaries. Novo Nordisk’s 70% price cut on Wegovy reduces the cash-pay barrier. Foundayo at $149/month provides the cheapest FDA-approved GLP-1 option. And Eli Lilly’s authorized generic strategy provides additional price competition.

For patients currently using compounded semaglutide or tirzepatide, the transition path depends on insurance status. Medicare beneficiaries have the clearest alternative through the GLP-1 Bridge. Commercially insured patients should check formulary coverage. Cash-pay patients may find Foundayo ($149/month) competitive with compounded pricing.

The compounding pharmacy industry is expected to challenge the rule during the comment period, arguing that compounded versions serve patients with specific clinical needs such as allergies to inactive ingredients or requirements for non-standard doses.